| 3/1/2011 | CVLM | King Pharmaceuticals holders put $397.31 million 1.25% convertibles
|
| 1/31/2011 | CVLM | King tenders for all $400 million of 1.25% convertible notes due 2026
|
| 10/12/2010 | BKCVHY | Moody's may lift King Pharmaceuticals
|
| 10/12/2010 | CV | Market Commentary: Planned Ciena deal adds 0.5 point in the gray; existing Ciena notes mixed; King Pharma up
|
| 8/16/2010 | CV | Market Commentary: Convertibles muted; MannKind to price $100 million deal; King Pharma quiet as shares add
|
| 8/9/2010 | CV | Market Commentary: Convertibles quiet; Beckman Coulter recoups a little; King Pharmaceuticals down a point
|
| 5/11/2010 | BKCVHY | S&P affirms King, rates loan BBB-
|
| 4/28/2010 | BKCVHY | Moody's rates King Pharmaceuticals loans Ba1
|
| 4/7/2010 | CV | Market Commentary: Telvent rises in quiet debut; JA Solar, solar names active; Massey Energy extends losses
|
| 4/1/2010 | CV | Market Commentary: Corporate Office slips on debut; Micron trades up in line after earnings; Medtronic active
|
| 2/26/2010 | CVHY | King Pharmaceuticals files automatic shelf for stock, preferreds, debt
|
| 12/4/2009 | CV | Market Commentary: AMR, UAL extend gains; Take-Two holds up on hedge, stock sinks; King Pharma, Lions Gate up
|
| 5/11/2009 | BKBWCVHY | King Pharmaceuticals repays $48 million of debt in first quarter
|
| 11/24/2008 | CV | Market Commentary: Citigroup jumps on government rescue; B of A, Wachovia rise; Alpharma little changed on merger news
|
| 9/29/2008 | BKCV | S&P assigns King loan BBB-, convertibles BB
|
| 9/25/2008 | BKCV | Moody's rates King Pharma loans Ba2
|
| 8/25/2008 | BKCV | Moody's affirms King
|
| 8/22/2008 | CV | Market Commentary: Lehman jumps on speculation; King holds, Alpharma up on takeover bid; China Sunergy up on earnings
|
| 6/30/2008 | BKCV | S&P cuts King outlook to negative
|
| 5/21/2008 | BKCV | Moody's rates King Pharma SGL-1
|
| 11/20/2007 | CVHY | Moody's gives King loan Ba3
|
| 4/25/2007 | CV | S&P raises King Pharmaceuticals outlook to stable
|
| 3/28/2007 | CV | Moody's cuts King Pharmaceuticals view to negative
|
| 10/13/2006 | BTCV | King Pharmaceuticals calls 2.75% convertibles
|
| 9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
| 6/2/2006 | BTCV | King Pharmaceuticals gets tenders for 97.61% of 2.75% convertibles
|
| 5/26/2006 | BTCV | King Pharmaceuticals extends tender offer for 2.75% convertibles to June 2
|
| 4/28/2006 | BTCV | King Pharmaceuticals tenders for 2.75% convertibles
|
| 4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
| 3/30/2006 | BTCV | King Pharmaceuticals buys back $165 million of convertibles
|
| 3/27/2006 | CV | Market Commentary: Lucent preferreds climb on hopes of post-merger tender; Time Warner Telecom stock upgrade boost
|
| 3/24/2006 | BTCV | New Issue: King Pharmaceuticals prices $400 million of 20-year convertibles at 1.25%, up 0%
|
| 3/24/2006 | CV | Market Commentary: Cephalon setback positive for hedged players; Lucent strengthens on merger talks; BioMarin starts strong
|
| 3/23/2006 | CV | Market Commentary: BioMarin new deal gets thumbs-up; YRC weaker on poor outlook; Cephalon fails to get FDA nod
|
| 3/22/2006 | CV | Market Commentary: General Motors rises on union deal; Cephalon see-saws on drug prospects; Interpublic cut by S&P
|
| 3/22/2006 | BTCV | King Pharmaceuticals to offer $400 million of 20-year convertibles talked at 0.75%-1.25%, up 20%-25%
|
| 3/22/2006 | BTCV | King Pharmaceuticals to repurchase, redeem 2.75% convertible debentures
|
| 9/29/2005 | BKBTCV | S&P affirms King Pharmaceuticals, off watch
|
| 7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
| 4/21/2005 | BKCV | Moody's confirms King Pharmaceuticals
|
| 2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
| 2/28/2005 | BKCV | S&P cuts King Pharma view to negative
|
| 12/14/2004 | BKCV | S&P: King Pharma watch to developing
|
| 12/1/2004 | BKCV | Moody's cuts King Pharma loan to Ba2, converts to Ba3
|
| 7/26/2004 | BKCV | Moody's: King Pharma uncertain
|
| 7/26/2004 | BKCV | S&P: King Pharma on positive watch
|
| 7/26/2004 | CV | Market Commentary: King Pharma soars on merger; Boise Cascade higher on split; Marshall & Ilsley deal emerges
|
| 7/13/2004 | BKCV | S&P lowers King Pharma
|
| 5/7/2004 | CV | Moody's may lower King Pharma
|
| 5/6/2004 | CV | S&P: King Pharma on negative watch
|
| 3/12/2004 | CV | Market Commentary: King Pharma converts better as stock hurt by FDA ruling; Placer Dome bid up by volatility players
|
| 5/21/2003 | CV | Market Commentary: Providian's new paper soars to 104.5; Elan gains on deal for King sale; new deals continue to flow
|
| 4/29/2003 | CV | Market Commentary: Secondary activity picks up on influx of earnings reports; flow of small new issues continues
|
| 4/25/2003 | CV | Market Commentary: Amazon rise burns heavy hedges; Emulex bonds hold on stock drop; distressed buyers remain active
|
| 4/2/2003 | CV | Market Commentary: Allied Waste deal stands pat; energy names firm on hope from Reliant's bank victory
|
| 3/18/2003 | CV | Market Commentary: Mandalay prices at record premium among flurry of new deals; secondary players in hiding
|
| 3/17/2003 | CV | Market Commentary: Markets go green on war visibility; spate of deals hold promise for busy week
|
| 3/11/2003 | CV | Market Commentary: Interpublic prices, Arris launches $100 million; King Pharma dives on SEC investigation
|
| 2/11/2003 | CV | Moody's cuts King Pharmaceuticals outlook
|
| 1/30/2003 | CV | S&P raises Lennar to investment grade
|
| 1/30/2003 | CV | Market Commentary: Micron trading lighter as outright buyers hold on; several drug issues gain
|
| 6/21/2002 | CV | Market Commentary: Profits taken in defense names, buyers seen for insurance
|
| 5/22/2002 | CV | Market Commentary: Adelphia firms on buzz of Rigas deal; Berkshire surprises with overnighter
|
| 4/10/2002 | CV | Deutsche analysts say credit work provides insight for generic drug picks
|
| 4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
| 3/14/2002 | CV | Moody's cuts Brightpoint convertible to Ca
|
| 3/13/2002 | CV | S&P rates new Lucent convertible at CCC+
|
| 2/19/2002 | CV | Market Commentary: Convertibles lower on more selling after long weekend
|
| 11/6/2001 | CV | Market Commentary: Convertible market gains with stocks on rate cut, new deals
|
| 11/2/2001 | CV | New Issue: King Pharmaceuticals $300 mln 20-year cvt debs yield 2.75%, up 32%
|
| 11/2/2001 | CV | Market Commentary: King Pharmaceuticals trades up further after pricing; small deals join calendar
|
| 11/1/2001 | CV | Market Commentary: Broad rise in convertibles but eagerly awaited King Pharmaceuticals delayed
|
| 10/31/2001 | CV | Market Commentary: Convertible market bounces with stocks, new deal pricing
|
| 10/31/2001 | CV | S&P rates SuperValu convertible at BBB
|
| 10/30/2001 | CV | Market Commentary: Convertible market drops as stocks plummet, but buyers emerge late
|
| 10/29/2001 | CV | Market Commentary: Convertible market marked down in quiet session as stocks plunge
|
| 10/26/2001 | CV | Market Commentary: Convertible market surges with $2.6 bln of new paper
|
| 10/25/2001 | CV | Market Commentary: Convertible market higher, new deals get tighter
|
| 10/24/2001 | CV | Market Commentary: Convertible market higher as $1 bln in new deals emerge
|
| 10/24/2001 | CV | King Pharma $300 mln convertibles talked at 2.75-3.25% yield, up 28-32%
|
